COVID-19 vaccines have been authorized in the U.S. for a year and a half, with the FDA progressively expanding their clearances to cover broader and broader swathes of the population. Yet they are still unavailable to the youngest children, who remain unprotected from waves of infection generated by the emergence of new variants.
The challenge for drugmakers has been to develop and test smaller doses that would be as safe and effective in younger children as they’ve been proven to be in older teens and adults.
